mivacurium and Deficiency-Diseases

mivacurium has been researched along with Deficiency-Diseases* in 2 studies

Other Studies

2 other study(ies) available for mivacurium and Deficiency-Diseases

Article	Year
[Mivacurium and prolonged curarization]. Annales francaises d'anesthesie et de reanimation, 1995, Volume: 14, Issue:6 Topics: Butyrylcholinesterase; Deficiency Diseases; Homozygote; Humans; Isoquinolines; Mivacurium; Monitoring, Intraoperative; Neuromuscular Nondepolarizing Agents	1995
[Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency]. Annales francaises d'anesthesie et de reanimation, 1995, Volume: 14, Issue:6 Mivacurium is a new neuromuscular blocking agent with a short acting time of about 30 min, due to a fast hydrolysis by pseudocholinesterases. This metabolism carries a risk for prolonged neuromuscular block in case of an acquired or congenital pseudocholinesterase deficiency. We report the case of a 75-year-old woman who experienced a neuromuscular block prolonged for 10 h after a single dose of 0.35 mg.kg-1 of mivacurium, because of a major pseudocholinesterase (1800 UI.L-1, normal value: 5400-13200 UI.L-1). The likely cause was a congenital deficiency by a homozygote genetic mutation, as usual causes of an acquired deficiency had been eliminated. Topics: Aged; Anesthesia Recovery Period; Anesthesia, General; Butyrylcholinesterase; Deficiency Diseases; Female; Homozygote; Humans; Hysterectomy; Isoquinolines; Mivacurium; Neuromuscular Junction; Neuromuscular Nondepolarizing Agents	1995

Article

Year

[Mivacurium and prolonged curarization].

Annales francaises d'anesthesie et de reanimation, 1995, Volume: 14, Issue:6

Topics: Butyrylcholinesterase; Deficiency Diseases; Homozygote; Humans; Isoquinolines; Mivacurium; Monitoring, Intraoperative; Neuromuscular Nondepolarizing Agents

1995

[Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency].

Annales francaises d'anesthesie et de reanimation, 1995, Volume: 14, Issue:6

Mivacurium is a new neuromuscular blocking agent with a short acting time of about 30 min, due to a fast hydrolysis by pseudocholinesterases. This metabolism carries a risk for prolonged neuromuscular block in case of an acquired or congenital pseudocholinesterase deficiency. We report the case of a 75-year-old woman who experienced a neuromuscular block prolonged for 10 h after a single dose of 0.35 mg.kg-1 of mivacurium, because of a major pseudocholinesterase (1800 UI.L-1, normal value: 5400-13200 UI.L-1). The likely cause was a congenital deficiency by a homozygote genetic mutation, as usual causes of an acquired deficiency had been eliminated.

Topics: Aged; Anesthesia Recovery Period; Anesthesia, General; Butyrylcholinesterase; Deficiency Diseases; Female; Homozygote; Humans; Hysterectomy; Isoquinolines; Mivacurium; Neuromuscular Junction; Neuromuscular Nondepolarizing Agents

1995